TCGA-97-8174-01A-11R-2287-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.320
- UV_RESPONSE_DN+0.270
- TGF_BETA_SIGNALING+0.240
- BILE_ACID_METABOLISM+0.190
- HEME_METABOLISM+0.190
- NOTCH_SIGNALING+0.190
- WNT_BETA_CATENIN_SIGNALING+0.190
- ANGIOGENESIS+0.180
- COAGULATION+0.180
- MYOGENESIS+0.160
Top 10 suppressed
- E2F_TARGETS-0.660
- MYC_TARGETS_V2-0.610
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V1-0.560
- MTORC1_SIGNALING-0.530
- CHOLESTEROL_HOMEOSTASIS-0.450
- GLYCOLYSIS-0.380
- DNA_REPAIR-0.370
- TNFA_SIGNALING_VIA_NFKB-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-03717 | — | cohortA1 | 0.887 |
| 2 | SRR8613705 | — | A | 0.886 |
| 3 | TCGA-97-8172-01A-11R-2287-07 | — | cohortA1 | 0.885 |
| 4 | TCGA-86-8668-01A-11R-2403-07 | — | cohortA1 | 0.877 |
| 5 | TCGA-50-5942-01A-21R-1755-07 | — | cohortA1 | 0.869 |
| 6 | 94e6fbec-4eff-4ea5-a815-540bfbc8293b | — | — | 0.864 |
| 7 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.860 |
| 8 | TCGA-AC-A8OS-01A-12R-A41B-07 | — | A | 0.857 |
| 9 | TCGA-73-7498-01A-12R-2187-07 | — | cohortA2 | 0.857 |
| 10 | TCGA-BH-A0HP-01A-12R-A084-07 | — | A | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |